Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from...

ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of ...

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon ...

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinic...

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target fro...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price ta...

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported a loss for the fourth quarter on Monday.

Oppenheimer analyst Matthew Biegler maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and raises the price targ...